ACIP Upgrades Child Vaccine Booster Recommendation To ‘Should’

Not only should children age 12 to 15 get a booster, but 16- and 17-year-olds who previously 'may' get a booster, now also 'should' get one, the CDC advisory committee said.

Booster shot
ACIP members recommended children 12 to 15 book a booster shot five months after their primary COVID-19 vaccination. • Source: Alamy

“Should” outdueled “may” as US Centers for Disease Control and Prevention advisors recommended children age 12 to 17 who received the Pfizer Inc./BioNTech SE COVID-19 vaccine also obtain a booster.

The Advisory Committee on Immunization Practices voted 13-1 on 5 January that the CDC use its strongest possible language to encourage the additional jab for 12- to 15-year-olds and elevated...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Vaccines

More from Pink Sheet

EMA Touts Faster Global Post-Approval Changes Via Regulatory Reliance

 

The European Medicines Agency says that a regulatory reliance pilot that it is supporting to speed up assessments of post-approval changes appears to be accelerating evaluation timelines in non-EU countries.

UK And US Regulators In Sync On RWD External Control Arms

 
• By 

The UK regulator’s draft guideline on the use of external control arms based on real-world data reflects concepts similar to those outlined by the US Food and Drug Administration.

New EU Approvals

 

The Pink Sheet's list of EU centralized approvals of new active substances has been updated to include two new products, one of which is Vyjuvek, Krystal Biotech's advanced therapy for treating dystrophic epidermolysis bullosa.